FDA Inspection 963196 — Akrimax Pharmaceuticals, LLC
The FDA completed an inspection of Akrimax Pharmaceuticals, LLC on February 17, 2016 in Cranford, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 17, 2016
- Fiscal Year
- 2016
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Cranford, NJ (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)